Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lilly's Carroll: Let's Debate Pricing But Don't Lump Us With Turing

This article was originally published in Scrip

Executive Summary

At the recent BIO-Europe meeting, held in Munich, Germany, Eli Lilly & Co's senior vice president of corporate business development Darren Carroll, in an exclusive interview with Scrip, highlighted his expectations for 2016 and concerns for innovative pharmaceutical companies being tarred with the same brush as current businesses which are under the spotlight for unfounded soaring drug prices in the US.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register